Services on Demand
- Cited by SciELO
- Access statistics
On-line version ISSN 1414-431X
Braz J Med Biol Res vol.34 no.8 Ribeirão Preto Aug. 2001
Braz J Med Biol Res, August 2001, Volume 34(8) 977-983
Isolation of bovine plasma albumin by liquid chromatography and its polymerization for use in immunohematology
Divisão de Pesquisa e Desenvolvimento Industrial, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, SP, Brasil
Material and Methods
Results and Discussion
Correspondence and Footnotes
The aim of the method described here is to remove hemoglobin, the major contaminant in the bovine plasma obtained from slaughterhouses, by adding a mixture of 19% cold ethanol and 0.6% chloroform, followed by fibrinogen and globulin precipitation by the Cohn method and nonspecific hemagglutinin by thermocoagulation. The experimental volume of bovine plasma was 2,000 ml per batch. Final purification was performed by liquid chromatography using the ion-exchange gel DEAE-Sepharose FF. The bovine albumin thus obtained presented ³99% purity, a yield of 25.0 ± 1.2 g/l plasma and >71.5% recovery. N-acetyl-DL-tryptophan (0.04 mmol/g protein) and sodium caprylate (0.04 mmol/g protein) were used as stabilizers and the final concentration of albumin was adjusted to 22.0% (w/v), pH 7.2 to 7.3. Viral inactivation was performed by pasteurization for 10 h at 60oC. The bovine albumin for the hemagglutination tests used in immunohematology was submitted to chemical treatment with 0.06% (w/v) glutaraldehyde and 0.1% (w/v) formaldehyde at 37oC for 12 h to obtain polymerization. A change in molecular distribution was observed after this treatment, with average contents of 56.0% monomers, 23.6% dimers, 12.2% trimers and 8.2% polymers. The tests performed demonstrated that this polymerized albumin enhances the agglutination of Rho(D)-positive red cells by anti-Rho(D) serum, permitting and improving visualization of the results.
Key words: bovine albumin, production; bovine albumin, purification; bovine albumin, polymerization; bovine albumin, downstream process
Bovine albumin is very similar to human albumin in terms of structure and physicochemical properties. Its molecular weight is 66,300 to 69,000 Dalton, and the molecule consists of a single and quite long, compactly folded polypeptide chain of about 582 amino acid residues in length with an almost spherical configuration (1-3).
Bovine albumin plays a prevalent role as a basic component of several biological reagents for diagnostic use, mainly for immunohematological tests, such as the antisera used in reactions for in vitro detection of erythrocyte antigens or of specific antibodies in blood recipients or donors. Bovine albumin was first used as a diluent of anti-Rh serum in 1945 and is widely used today. This serum component may influence the hemagglutination reaction, enhancing the erythrocyte agglutination for better visualization and easier reading of the results, based on factors such as zeta potential reduction, increase of the dielectric constant, release of bound water, change of red cell shape, and reduction in ionic strength (4).
In 1969, Jones et al. (5) reported that polymerized bovine albumin was more effective in potentiating direct agglutination, and that potentiation was directly related to the degree of polymer content. This polymerization has been reported to appear in albumin obtained by ethanol fractionation subjected to freeze-drying, heating, etc., but Reckel and Harris (6) showed that chemically polymerized albumin also presents good serological properties enhancing direct agglutination by a covalent link. The most frequently mentioned theory is that of Pollack et al. (7) who proposed that bovine albumin causes red cells to approach one another more closely. Polymerized bovine albumin raises the dielectric constant of the medium, which reduces the zeta potential. In spite of the great technological achievements in the production and purification of human albumin for therapeutic use, there is an enormous gap regarding production and purification of bovine albumin for diagnostic use. Thus, we developed a method to obtain pure albumin for diagnostic use, free of impurities when used as a stabilizer or in in vitro tests, and presenting high-quality performance compared to the international products. Since the bovine plasma obtained from slaughterhouses shows a high degree of hemolysis, with a dark red color, it is necessary first of all to remove hemoglobin with 0.6% chloroform and 19.0% cold ethanol (-20oC) at pH 7.2 (8,9). All the globulins (alpha, beta and gamma) are removed by the method of Cohn et al. (10) and nonspecific hemagglutinin by thermocoagulation (11). Final purification is performed by liquid chromatography using the anion ion-exchange gel DEAE-Sepharose FF (Pharmacia, Uppsala, Sweden) (8,12,13).
Bovine plasma was collected at a slaughterhouse into 10% sodium citrate. Each experiment was performed with 2,000 ml of this plasma and pH was adjusted to 7.2 with acetate buffer, pH 4.0 (4 M sodium acetate and 10 M acetic acid). A mixture of ethanol and chloroform was slowly added under homogenization to a final concentration of 19% ethanol and 0.6% chloroform. This mixture was kept at 4oC and was homogenized for an additional 20 min in order to obtain complete hemoglobin precipitation. After this step, plasma was kept in a cold room at -5oC overnight for g-globulin precipitation. The precipitate consisting of hemoglobin and g-globulin was removed by centrifugation at 2,500 g for 10 min at -5oC (Sorvall RC-3B plus, Du Pont, Wilmington, DE, USA) and discarded. The pH of supernatant I (Figure 1) was adjusted to 6.0 with acetate buffer solution, pH 4.0, under homogenization for about 30 min at -5oC and the preparation was left to stand for 6 h to precipitate a- and ß-globulin, which were removed by centrifugation as described above and discarded. Supernatant II thus obtained (Figure 1) was submitted to diafiltration with tangential ultrafiltration with a Pellicon cassette system (NMWL PLGC, Millipore, Bedford, MA, USA) to remove ethanol and chloroform. The supernatant was concentrated to 7% protein and the volume after this step was 1,000 ml; pH was adjusted to 6.6 with 0.5 M NaOH and conductivity was adjusted to 5.0 mS/cm with NaCl. Sodium caprylate was then added at the proportion of 0.16 mmol/g albumin, and ethanol was added to a final concentration of 9% (v/v); this preparation was submitted to heat treatment until it reached a temperature of 70oC within approximately 1 h and 30 min. The preparation was then cooled to 20oC, with pH adjusted to 4.5 with 1.0 M HCl, and kept at 4oC overnight to precipitate fatty acids, nonspecific hemagglutinin and residual globulin. The precipitates were removed by centrifugation at 2,500 g for 10 min at 4oC and discarded. Supernatant III (Figure 1) was clarified with a 60-S deep filter (Zeta plus, Cuno, Meriden, CT, USA) in a cold room at +4oC. After filtration, the operating temperature was 22oC, the filtrate pH was adjusted to 5.4 with 1.0 M NaOH, and conductivity was adjusted to 1.40 mS/cm by the addition of deionized water. The filtrate volume, which became 7,000 ml at this step, was reduced to 2,000 ml with a 10-kDa Pellicon cassette system. The preparation was then applied to an XK-50/30 chromatographic column packed with 320 ml of ion-exchange gel, DEAE-Sepharose FF, previously equilibrated with acetate buffer, pH 5.4 (20 mM sodium acetate, 1.40 mS/cm conductivity), and processed in 4 cycles with a linear flow of 65 cm/h.
After sample application, corresponding to the first cycle, the chromatographic column was washed with 2 total gel volumes (TV) of the equilibrating buffer solution to remove proteins not adsorbed on the gel. The adsorbed albumin was eluted with 2 TV of buffer solution, pH 4.5 (2 mM sodium acetate and 1.75 mS/cm conductivity), and the other proteins which were still adsorbed on the gel were removed with 2 TV of buffer solution, pH 4.0 (150 mM sodium acetate and 8.0 mS/cm conductivity).
For the subsequent cycle, the chromatographic column with the gel was re-equilibrated according to the step described above until the fourth cycle was completed. The gel was regenerated with 2 TV 0.5 M NaOH and stored in 10 mM NaOH, as recommended by Pharmacia. The albumin eluted from the DEAE-Sepharose FF gel was concentrated to 25% (w/v) and formulated by the addition of 0.04 mmol sodium caprylate/g albumin, 0.04 mmol N-acetyl-DL-tryptophan/g albumin (14), and 0.1% sodium azide as stabilizers, pH 7.2, with a conductivity of 6.0 mS/cm. After formulation, bulk viral inactivation was performed by pasteurization at 60oC for 10 h and the preparation was filtered through a sterilizing 0.22-µm Millipore membrane. The final concentration of bovine albumin after the formulation was adjusted to 22% (w/v) (Figure 1).
In order to obtain proper polymerization for the hemagglutination tests, prior to the above formulation step part of the 25% bovine albumin was submitted to a treatment with 0.06% glutaraldehyde (15) and 0.1% formaldehyde, pH 7.4, and 9.0 mS/cm conductivity at 37oC for 12 h. After treatment, glutaraldehyde and formaldehyde were removed by diafiltration and the product was concentrated to 25% (w/v). The formulation and viral inactivation by pasteurization were performed as already described. The final concentration was adjusted to 22% (w/v), pH 7.2 to 7.3, at 6.0 mS/cm conductivity (Figure 2). Using the proposed method we produced 20 lots of high-quality bovine albumin.
[View larger version of this image (27 K GIF file)]
[View larger version of this image (8 K GIF file)]
Protein concentration was determined by the biuret method. Albumin purity was determined by electrophoresis on a cellulose acetate membrane and concentration was measured with a Helena H. Junior 24 densitometer (France S.A., Saint Leu la Fôret, France). Immunoelectrophoresis was performed on 1% agarose gel (16), using the rabbit anti-total bovine plasma serum (Sigma, St. Louis, MO, USA). The relative content of polymers, dimers and monomers was determined on an XK-16/60 column packed with Superdex 200 HR gel (Pharmacia), and native polyacrylamide gel electrophoresis was carried out on 5 to 15% gradient gels at 110 V for 1:20 h in 25 mM Tris to 0.192 M glycine buffer, pH 8.3. The plasma hemoglobin-free content was determined by the peroxidase method (17). The hemagglutination enhancement by polymerized bovine albumin was tested by standard antibody screening tests. Anti-Rho(D) antisera were serially diluted and Rho(D)-positive and Rho(D)-negative erythrocytes were used. The color intensity of albumin was determined with a Beckman Du-65 spectrophotometer at 403 nm absorbance.
The characteristics of 22% (w/v) bovine albumin are presented in Table 1.
The major objective of the present study was to remove hemoglobin and to adapt the process of human albumin fractionation for bovine albumin production, in view of the lack of scientific publications of technologies for bovine albumin purification. There are patents held by a few foreign manufacturers.
The state-of-the art technology used for the production of human albumin was modified and adapted to the production of bovine albumin. Since bovine plasma obtained from slaughterhouses contains a significant amount of hemolyzed blood (54 mg/dl free hemoglobin in plasma), the first step was to remove hemoglobin at the very beginning of the process, otherwise it would persist up to the final product, conferring a highly disagreeable dark brown color to it and also possibly precipitating during storage. Another point to consider is the presence of nonspecific hemagglutinin activity in bovine plasma, which shows average titers of 1:1024 for anti-A and 1:256 for anti-B with human red cells A and B, respectively. Therefore, when albumin purification is not well processed, part of these impurities may remain in the final product, interfering with the immunohematological tests. Thus the nonspecific hemagglutinin activity was denatured and precipitated by heating the product up to 70oC with 9% ethanol (11). It is advisable to use only sodium caprylate as stabilizer for bovine albumin, since its presence at concentration of ³0.08 mmol/g albumin interferes with the immunohematological tests, impairing the interpretation and detection of erythrocyte antibodies from blood recipients or donors. We used a mixture of sodium caprylate (0.04 mmol/g albumin) and N-acetyl-DL-tryptophan (0.04 mmol/g albumin) (14) to prevent this problem. With this procedure, bovine albumin showed good stability without interfering with the immunohematological tests. Analysis of the molecular distribution of bovine albumin purified by the described method showed 94.4% monomers, 4.8% dimers and 0.8% polymers, as compared to 90.5% monomers, 8.8% dimers and 0.7% polymers for bovine albumin from Sigma (Lot No. 118H0594) analyzed in parallel. In contrast to 20% human albumin for therapeutic use, which must present a minimum amount of polymers (less than 5%), as dictated by Resolution RDC-46 of May 18, 2000 of the Health Ministry of Brazil (18), the presence of these compounds in bovine albumin potentiates the reactions in hemagglutination tests, permitting a better visualization and interpretation of the results (6). In order to increase the polymer content in bovine serum albumin, a treatment with glutaraldehyde/formaldehyde was performed, with concentrations ranging from 0.02/0.00% to 0.08/0.15% and the preparation was heated in a water bath at 37oC for 12 h. The best result was obtained with 0.06% glutaraldehyde and 0.10% formaldehyde. It was then possible to obtain on average 56.0% monomers, 23.6% dimers, 12.2% trimers, and 8.2 polymers, as analyzed by Superdex 200 HR gel filtration and polyacrylamide gel electrophoresis (Figures 3 and 4, and Table 2). A mixture of glutaraldehyde and formaldehyde was used, since glutaraldehyde, by inducing the formation of polymers, also provokes an increase of the strong yellow color of albumin, whereas the presence of formaldehyde prevents the alteration of the normal color of albumin. This polymerized albumin did not present the phenomenon of rouleaux or nonspecific agglutination in hemagglutination tests. Titration tests with anti-Rho(D) serum using albumin with different degrees of polymerization were also performed, and the results were compared to those for the bovine albumin from Sigma. The albumin treated with 0.06% glutaraldehyde improved the agglutination with two additional titers in the dilution without causing interference (Table 3).
We conclude that the procedure described here yields a high-quality product of light yellow color similar to human albumin, which complies with requirements for diagnostic use.
[View larger version of this image (5 K GIF file)]
[View larger version of this image (28 K JPG file)]
1. Tanaka K (1987). Fracionamento de plasma bovino para isolamento da albumina e sua liofilização. Master's thesis, Faculdade de Ciências Farmacêuticas, USP, São Paulo, SP, Brazil. [ Links ]
2. Rochu D (1986). L'albumine humaine. Revue Française de Transfusion et Immuno-Hematologie, 29: 13-33. [ Links ]
3. Murozuka T, Moriwara M, Ito H, Sekiguchi S, Naiki M, Tanaka K & Aoyama T (1990). Bovine albumin, like protein in commercial human albumin for clinical use. Vox Sanguinis, 59: 1-5. [ Links ]
4. Sosler SD (1985). Enhancement media for transfusion testing. In: Ellisor SS & Wallis ME (Editors), Blood Bank Reagents: What to Use and When. American Association of Blood Banks, Arlington, VA,11-41. [ Links ]
5. Jones JM, Kekwich RA & Goldsmith KLG (1969). Influence of polymers on the efficiency of serum albumin as a potentiator of incomplete Rh agglutinins. Nature, 224: 510-511. [ Links ]
6. Reckel RP & Harris J (1978). The unique characteristics of covalently polymerized bovine serum albumin solutions when used as antibody detection media. Transfusion, 18: 397-406. [ Links ]
7. Pollack W, Hager HJ, Reckel R, Toren DA & Singher HO (1965). A study of the forces involved in the second stage of hemagglutination. Transfusion, 5: 158-183. [ Links ]
8. Curling JM (1983). Separation of plasma proteins. In: Curling JM (Editor), Pharmacia Fine Chemicals AB. Pharmacia, Uppsala, Sweden. [ Links ]
9. Cabrera-Crespo J (1998). Produção de albumina a partir de placentas humanas. Doctoral thesis, Instituto de Química, USP, São Paulo, SP, Brazil. [ Links ]
10. Cohn EJ, Strong LE, Hughes Jr WL, Mulford DJ, Ashworth JN, Melin M & Taylor HL (1946). Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. Journal of the American Chemical Society, 68: 459-475. [ Links ]
11. Schneider W, Lefevre H, Fiedler H & McCarty LJ (1975). An alternative method of large scale, plasma fractionation for the isolation of serum albumin. Blut, 30: 121-134. [ Links ]
12. Tanaka K, Sawatani E, Nakao H, Dias GA & Arashiro F (1996). An alternative column chromatographic process for the production of human albumin. Brazilian Journal of Medical and Biological Research, 29: 185-191. [ Links ]
13. Tanaka K, Shigueoka EM, Sawatani E, Dias GA, Arashiro F, Campos TCXB & Nakao HC (1998). Purification of human albumin by the combination of the method of Cohn with liquid chromatography. Brazilian Journal of Medical and Biological Research, 31: 1383-1388. [ Links ]
14. Yu MW & Funlayson JS (1984). Stabilization of human albumin by caprylate and acetyltryptophanate. Vox Sanguinis, 47: 28-40. [ Links ]
15. King MJ (1987). Hemagglutination enhancement by bovine serum albumin is affected by octanoate, Reactive Blue 2 (Cibacron Blue), and polymer. Transfusion, 27: 302-308. [ Links ]
16. Grabar P & Williams Jr CA (1953). Immunoelectrophoresis. Biochimica et Biophysica Acta, 10: 193-200. [ Links ]
17. Wu H (1923). Studies on hemoglobin: Ultra method for determination of hemoglobin as peroxidase. Biochemical Journal, 2: 198-199. [ Links ]
18. Diário Oficial da União (19/05/2000). Ministério da Saúde, Agência Nacional da Vigilância Sanitária, Resolução RDC-46 de 18/05/2000. [ Links ]
19. Dunsford I & Bowley CC (1967). Techniques in Blood Grouping. Vol. II. 2nd edn. Charles C. Thomas Publisher, Springfield, IL, 285-287. [ Links ]
Address for correspondence: K. Tanaka, Divisão de Pesquisa e Desenvolvimento Industrial, Fundação Pró-Sangue Hemocentro de São Paulo, Av. Enéas C. Aguiar, 155, 1º andar, 05403-000 São Paulo, SP, Brasil. E-mail: email@example.com
Publication supported by FAPESP. Received October 23, 2000. Accepted May 29, 2001.